Ticker > Company >

Dr. Reddy''s Lab share price

Dr. Reddy''s Laboratories Ltd.

NSE: DRREDDY BSE: 500124 SECTOR: Pharmaceuticals & Drugs  297k   1k   240

1338.80
-8.00 (-0.59%)
NSE: Today, 11:34 AM

Price Summary

Today's High

₹ 1349.7

Today's Low

₹ 1334.3

52 Week High

₹ 1421.49

52 Week Low

₹ 1020

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

111732.38 Cr.

Enterprise Value

111308.38 Cr.

No. of Shares

83.46 Cr.

P/E

20.89

P/B

3.87

Face Value

₹ 1

Div. Yield

0.6 %

Book Value (TTM)

₹  345.77

CASH

1216.9 Cr.

DEBT

792.9 Cr.

Promoter Holding

26.64 %

EPS (TTM)

₹  64.1

Sales Growth

14.86%

ROE

19.54 %

ROCE

25.52%

Profit Growth

66.18 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Dr. Reddy''s Laboratories Ltd.

Molflu OMEZ Nise Stamlo Clamp Econorm Razo SENQUEL-F KETOROL ATOCOR MINTOP VENUSIA Glimy Telsartan Activ Alfoo Atarax Cetzine Cresp Doxt-SL Dutas-T Reclimet Reditux Reswas Vantej Xyzal Molnupiravir capsules

Index Presence

The company is present in 48 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.86%
3 Year13.43%
5 Year12.89%

Profit Growth

1 Year66.18%
3 Year25.7%
5 Year27.73%

ROE%

1 Year19.54%
3 Year14.12%
5 Year15.45%

ROCE %

1 Year25.52%
3 Year18.7%
5 Year18.5%

Debt/Equity

0.0329

Price to Cash Flow

32.39

Interest Cover Ratio

266.656

CFO/PAT (5 Yr. Avg.)

1.10892490932047

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 26.64 0.00
Dec 2024 26.64 0.00
Sep 2024 26.64 0.00
Jun 2024 26.65 0.00
Mar 2024 26.65 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 25.6955975183994% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 266.656.
  • The Company has been maintaining an effective average operating margins of 24.19728% in the last 5 years.
  • Company’s PEG ratio is 0.31655111841954.
  • The company has an efficient Cash Conversion Cycle of 18.7778 days.
  • Company has a healthy liquidity position with current ratio of 3.2145.
  • The company has a good cash flow management; CFO/PAT stands at 1.10892490932047.

 Limitations

  • The company has shown a poor revenue growth of 13.4331549527408% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 5104.8 5841.2 6696.3 5015 5562.9
Total Expenditure 3726.2 3888.2 3974.7 3822.6 4119.9
Operating Profit 1378.6 1953 2721.6 1192.4 1443
Other Income 212.7 217.8 207.6 235.4 414.4
Interest 5.9 7.1 28.4 43.3 31.1
Depreciation 246.2 249.8 260 265.1 264.5
Exceptional Items 0 0 0 0 0
Profit Before Tax 1339.2 1913.9 2640.8 1119.4 1561.8
Tax 304.4 496.7 758.7 270 361.1
Profit After Tax 1034.8 1417.2 1882.1 849.4 1200.7
Adjusted EPS (Rs) 12.41 16.99 22.57 10.18 14.4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 11850.4 13349.1 14405.2 16962.5 19483.8
Total Expenditure 8980.8 10212.3 11811.1 12747.7 13557.4
Operating Profit 2869.6 3136.8 2594.1 4214.8 5926.4
Other Income 743.2 801.1 482 591.3 862.3
Interest 47.8 46.7 38 16.9 21.8
Depreciation 789.2 835 814.3 923.2 975.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 2775.8 3056.2 2223.8 3866 5791.3
Tax -161.9 869.8 600.6 1253.2 1449.3
Net Profit 2937.7 2186.4 1623.2 2612.8 4342
Adjusted EPS (Rs.) 35.35 26.28 19.51 31.37 52.06

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 83.1 83.2 83.2 83.3 83.4
Total Reserves 15108.8 16900.5 18253 20390.9 24157.4
Borrowings 19.3 17.7 19.7 28.6 49.5
Other N/C liabilities -528.8 -186.9 75.2 432.3 530.9
Current liabilities 4180.5 4560.3 6045.1 4439.7 5538.1
Total Liabilities 18862.9 21374.8 24476.2 25374.8 30359.3
Assets
Net Block 4433.9 5844.3 6150.5 7195.3 7589.1
Capital WIP 384.1 877.1 1186.4 899.1 1171.9
Intangible WIP 27.7 23.7 13.9 25.3 39.1
Investments 3367.1 3392.2 3018.7 3248.6 3216.3
Loans & Advances 542 293.2 409.8 324.6 507.2
Other N/C Assets 1.4 0.1 202.6 0 33.4
Current Assets 10106.7 10944.2 13494.3 13681.9 17802.3
Total Assets 18862.9 21374.8 24476.2 25374.8 30359.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2775.8 3056.2 2223.8 3866 5791.3
Adjustment 681.8 273.3 845.1 1045.8 602
Changes in Assets & Liabilities -1141.5 632.7 -1241.4 923.7 -1624.1
Tax Paid -476.9 -448 -488.8 -782.7 -1319.5
Operating Cash Flow 1839.2 3514.2 1338.7 5052.8 3449.7
Investing Cash Flow -1689.2 -1453.6 -1990.1 -3403.1 -3428.7
Financing Cash Flow -224.1 -794.3 505.5 -2696.9 68.1
Net Cash Flow -74.1 1266.3 -145.9 -1047.2 89.1

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 26.65 26.65 26.64 26.64 26.64
anuradha gunupati 0.01 0.01 0.01 0.01 0.01
g v prasad - 11.52 11.52 11.52 11.52
gunupati venkateswara pra... 1.52 1.52 1.52 1.52 1.52
kallam satish reddy huf 3.31 3.31 3.31 3.31 3.31
satish reddy kallam 0.54 9.61 9.60 9.60 10.27
samrajyam reddy kallam 0.67 0.67 0.67 0.67 -
aps trust 20.59 - - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 73.35 73.35 73.36 73.36 73.36
first sentier investors i... 2.32 2.32 2.32 2.32 1.45
icici prudential value di... - 1.17 2.09 2.38 3.79
investor education and pr... - 0.20 0.20 0.30 0.30
life insurance corporatio... 5.05 5.52 5.60 6.50 7.19
nippon life india trustee... - 1.02 1.33 1.83 1.95
nps trust-a/c sbi pension... 2.30 2.53 2.66 2.55 2.45
parag parikh flexi cap fu... - - - - 1.28
sbi nifty index fund - 1.29 1.49 1.29 1.37
hdfc trustee company ltd.... 1.62 1.75 1.34 - -
mirae asset nifty india m... - 1.11 - - -
government of singapore 1.02 - - - -
investor education and pr... 0.20 - - - -
sbi-etf nifty 50 1.42 - - - -

Ratings & Research Reports

Company Presentations

Company News

Dr. Reddy's Laboratories, Alvotech enter into license agreement 5 Jun, 10:12 AM Dr. Reddy’s Laboratories informs about press release 5 Jun, 9:37 AM USFDA completes GMP inspection at Dr. Reddy's Telangana API facility 26 May, 10:59 AM USFDA completes GMP inspection at Dr. Reddy's API Middleburgh facility in New York 17 May, 3:05 PM Dr Reddys Laboratories informs about disclosure 17 May, 12:33 PM Dr Reddys Laboratories informs about press release 10 May, 5:40 PM Dr. Reddy's Laboratories reports 21% rise in Q4 consolidated net profit 10 May, 2:52 PM Dr. Reddy’s Laboratories informs about audio recording of earnings call 10 May, 9:59 AM Dr Reddys Laboratories informs about dividend updates 9 May, 5:38 PM Dr. Reddy's Lab - Quaterly Results 9 May, 4:46 PM Dr. Reddy's Lab - Quaterly Results 9 May, 4:46 PM Dr. Reddy's Lab - Quaterly Results 9 May, 4:46 PM Dr. Reddy's Laboratories expands partnership with Sanofi Healthcare 29 Apr, 11:00 AM Dr. Reddy's arm recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection in US 23 Apr, 3:51 PM Dr. Reddy’s Laboratories informs about disclosure 16 Apr, 9:36 AM Dr. Reddy’s arm inks commercialization and license agreements for biosimilars 27 Mar, 3:08 PM Dr. Reddy's arm sells membership interests in Dr. Reddy’s Laboratories Louisiana 24 Mar, 3:00 PM Dr Reddys Laboratories informs about disclosure 20 Mar, 5:31 PM Dr Reddys Laboratories informs about analyst meet 12 Mar, 5:22 PM Dr. Reddy’s Laboratories informs about updates 25 Feb, 5:16 PM Dr. Reddy's gets EIR for API manufacturing facility in Hyderabad 25 Feb, 5:14 PM Dr. Reddy's Laboratories reports marginal rise in Q3 consolidated net profit 24 Jan, 11:43 AM Dr. Reddy’s Laboratories informs about audio recording of earnings call 24 Jan, 9:30 AM Dr. Reddy's Lab - Quaterly Results 23 Jan, 5:29 PM Dr. Reddy's Lab - Quaterly Results 23 Jan, 5:29 PM Dr. Reddy's Lab - Quaterly Results 23 Jan, 5:29 PM Dr. Reddy's arm to sell membership interests in DRLL 8 Jan, 2:11 PM Dr. Reddy's Laboratories’ arm incorporates wholly-owned subsidiary in Finland 24 Dec, 10:13 AM Dr. Reddy’s Laboratories informs about allotment of equity shares 20 Dec, 10:04 AM Dr. Reddy’s Laboratories submits press release 28 Nov, 11:30 AM Dr. Reddy’s Laboratories launches Toripalimab in India 28 Nov, 10:14 AM Dr.Reddy's Laboratories informs about investor conference 26 Nov, 3:40 PM Dr.Reddy's Laboratories informs about analyst meet 26 Nov, 3:35 PM Dr. Reddy's Laboratories’ arm recalling Morphine Sulfate extended-release tablets 18 Nov, 10:50 AM Dr. Reddy’s Laboratories informs about disclosure 14 Nov, 10:34 AM Dr. Reddy's to invest up to Rs 600 crore in step-down wholly owned subsidiary 7 Nov, 10:27 AM Dr. Reddy's Laboratories reports 9% fall in Q2 consolidated net profit 6 Nov, 11:43 AM Dr. Reddy's Lab - Quaterly Results 5 Nov, 4:07 PM Dr. Reddy's Lab - Quaterly Results 5 Nov, 4:07 PM Dr. Reddy's Lab - Quaterly Results 5 Nov, 4:07 PM Dr. Reddy's Laboratories launches drug to treat chronic constipation 29 Oct, 11:10 AM Dr. Reddy’s Laboratories informs about incorporation of step down wholly-owned subsidiary 5 Oct, 1:08 PM Dr. Reddy's Laboratories’ arm incorporates new wholly-owned subsidiary 5 Oct, 1:01 PM Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences 3 Oct, 9:38 AM Dr. Reddy's makes investment of $620 million in DRL SA 28 Sep, 2:50 PM Dr. Reddy’s Laboratories informs about disclosure 26 Sep, 9:48 AM USFDA completes GMP inspection at Dr. Reddy's Laboratories’ R&D centre 20 Sep, 6:10 PM Dr. Reddy’s Laboratories informs about disclosure 20 Sep, 5:36 PM Dr. Reddy's gets EIR for API manufacturing facility in Andhra Pradesh 6 Sep, 10:42 AM Dr. Reddy’s Laboratories informs about update 6 Sep, 10:20 AM

Dr. Reddy''s Lab Stock Price Analysis and Quick Research Report. Is Dr. Reddy''s Lab an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Reddy''s Lab and its performance over the period of time. Dr. Reddy''s Lab stock price today is Rs 1339.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Dr. Reddy''s Lab cash from the operating activity was Rs 3449.7 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Reddy''s Lab has a Debt to Equity ratio of 0.0329 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Reddy''s Lab , the EPS growth was 65.9827 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Reddy''s Lab has OPM of 30.4170644330162 % which is a good sign for profitability.
     
  • ROE: Dr. Reddy''s Lab have a average ROE of 19.5418 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Dr. Reddy''s Lab is Rs 1339.9. One can use valuation calculators of ticker to know if Dr. Reddy''s Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Dr. Reddy''s Lab
X